GlassScriptPhysician profile
Vincent P Keating
NPI 1871569103
$80,063.24
in general payments reported to CMS, 2019-2025
34 companies · $58K in 2025
The $58K reported for 2025 was more than what 96% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $919 · 2020: $250 · 2021: $598 · 2022: $422 · 2023: $1,829 · 2024: $18K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Food and Beverage: $3,558 · Consulting Fee: $400 · Travel and Lodging: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $73,750.00 |
| Food and Beverage | $3,558.24 |
| Consulting Fee | $400.00 |
| Travel and Lodging | $166.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $75,256.32 | 2019-2025 | General - Ep, Rhythmia Mapping System, Watchman Access System |
| Medtronic, INC. | $955.90 | 2021-2024 | Micra, Pulseselect, Selectsecure |
| Abbott Laboratories | $667.35 | 2020-2024 | Ensite Precision, Ensite, Gallant |
| Biotronik INC. | $647.45 | 2019-2025 | Edora 8 Dr-T, Amvia Edge, Acticor 7 Vr-T Dx |
| Novartis Pharmaceuticals Corporation | $616.59 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $314.31 | 2019-2024 | Xarelto |
| Pfizer INC. | $259.63 | 2019-2025 | |
| Philips North America LLC | $160.43 | 2020-2025 | (9520) Igt Devices Undivided, Angiosculpt Cv Rx |
| Novo Nordisk INC | $148.49 | 2023-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $134.98 | 2019-2024 | Farxiga, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $121.56 | 2019-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $95.98 | 2019 | |
| Kestra Medical Technology Services, INC. | $94.81 | 2024-2025 | Assure Wcd |
| Atricure, INC. | $70.39 | 2022-2025 | Synergy Ablation System |
| Merck Sharp & Dohme LLC | $60.73 | 2023-2024 | Verquvo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $55.35 | 2023-2025 | Amvuttra, Onpattro |
| E.R. Squibb & Sons, L.L.C. | $48.09 | 2022-2025 | Eliquis |
| Amgen INC. | $39.22 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.59 | 2023-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $28.13 | 2019 | |
| Medtronic Vascular, INC. | $27.73 | 2019-2020 | |
| Teleflex LLC | $25.79 | 2024 | Guideliner |
| Angiodynamics, INC. | $22.74 | 2020 | |
| Cardiofocus, INC. | $20.96 | 2019 | |
| Cardiva Medical, INC. | $19.45 | 2022 | |
| Bridgebio Pharma, INC. | $18.49 | 2025 | Attruby |
| Altathera Pharmaceuticals LLC | $17.70 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $17.58 | 2024 | Uptravi, Opsumit |
| Kiniksa Pharmaceuticals International, Plc | $15.55 | 2024 | Arcalyst |
| Otsuka America Pharmaceutical, INC. | $15.55 | 2019 | |
| Vifor Pharma, INC. | $15.53 | 2019 | |
| Astellas Pharma US INC | $15.20 | 2019 | |
| Elutia, INC. | $14.24 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Keating listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.